PMGC Holdings (ELAB) Embarks on Bold Growth Strategy

PMGC Holdings Inc. (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant milestone in PMGC’s journey as a diversified holding company.

The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments. It has notably strengthened PMGC’s balance sheet, reduced operational losses, and paved the way for new opportunities that align with the company's long-term vision.

Strategic Rationale: Think Bigger, Act Bold

The divestiture underscores PMGC's strategy to focus on acquiring transformative assets and businesses that deliver substantial growth and shareholder value. This sale frees the Company to look for bigger opportunities. Executive management’s goal is not incremental improvement but exponential growth through strategic acquisitions and steadfast execution.

Key Financial and Operational Highlights Post Sale

• Burn Rate Reduction: By eliminating a loss-generating subsidiary, PMGC ensures a leaner and more focused operational framework.
• Strengthened Financials: PMGC will receive approximately $1.1 million in Carmell Corporation stock and retains a lucrative 5% royalty on skincare revenues over the next five years, alongside milestone payment opportunities​.
• Growth Capital: Resources will now be channeled into high-potential assets, leveraging PMGC’s drive and expertise in creating shareholder value.

Why It Matters to Shareholders

This move demonstrates PMGC’s agility in adapting to market opportunities and its unwavering commitment to delivering shareholder value. The sale of Elevai Skincare is a step toward creating a portfolio of assets that reflects the company’s expansive vision and ambition.

For investors, this signals a moment of transition and opportunity. As PMGC positions itself to seize larger, more impactful opportunities, shareholders can look forward to the potential for increased returns, reduced risk, and sustainable growth.

Looking Ahead: Growth, Diversification, and Opportunity

PMGC is actively exploring accretive acquisitions and licensing opportunities in sectors poised for significant growth. The Company is focused on identifying undervalued assets and businesses that align with a vision of building a diversified and growth-oriented holding company.

PMGC Holdings Inc. will continue to expand its company portfolio with a focus on innovation, growth, and shareholder value creation. Current subsidiaries include:

Elevai Biosciences: a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com.

Elevai Research: a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation

PMGC Capital LLC: a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.

The current subsidiaries and pending opportunities underscore PMGC’s focus on thinking bigger and its drive to build a growth-oriented portfolio.

You May Also Be Interested In

• Lockheed Martin wins $35B THAAD interceptor contract
• U.S. Bancorp stress capital buffer stays at 2.6% through 2027, plans to raise dividend 3.8%
• Sinda Ltd. files for 17.75M share PO at $11.25-$13.25/sh